Market opportunity.
The 50 and older market our products serve is on a 70-percent growth trajectory through 2050.
A 1999 report valued the global arthritic joint reconstructive devices market at $4.5 billion, accelerating to $30.4 billion by 2025. The majority of this market growth was from lower extremities. In the 1970s and 1980s, knee replacement implants were still developing. In the next several years, advancements in both knee and hip implant technology and surgical techniques contributed to the 7X market increase after 1999. Today there are more than 1 million each of total knee replacements and hip replacements annually.
The thumb CMC joint is one of the most common sites for arthritis in the body. It is the most common site for surgical arthritic joint reconstruction in the upper limb. As treatment and technologies are improving, market growth for the CMC OA implant market globally is just beginning to mimic a similar growth response to that of knees and hips from several years ago.
Currently, the average American Surgeon of the Hand operates 35-40 times annually, with many well over 100 times. There are over 4,000 current ASSH members and an estimated 200,000+ U.S. procedures annually. With the adoption of a new, viable solution, this number is expected to increase towards the frequency of knee and hip replacements. European nations such as France, Germany, Italy and Switzerland currently each have ~40,000 CMC procedures annually.
Market research and data indicate that all arthritic joint markets will increase with the growth of the global 50+ population. The current population of 1.9 billion adults aged 50 and over is expected to balloon 70 percent by 2050 — to 3.2 billion — indicating tremendous potential for products that meet growing demands.
Arthritis will increase as the population grows and ages. Diagnosed cases through 2020 are shown, along with projections through 2040.
ZEPART® entry.
We’re driven to improve quality of life for patients through advanced solutions to problems in orthopedic medicine.
ZEPART® is Sandia Medical Technologies’ CMC joint implant offering in development.
Market opportunity: CMC thumb osteoarthritis is estimated to occur in up to 15% of adults total, including 15% of adults 50-59 and 24% of adults 60-92. The CMC OA market has a current CAGR of 8.1%. Globally, the market is already beginning to experience significant growth, similarly to knee and hip replacement markets 20-30 years ago when implant technology caught up with the clinical need. There are the same number of thumb CMC joints as there are knees and hips, and individuals are experiencing the same challenges as early knee and hip replacement patients and in a growing and aging population.
Our plans.
The ZEPART thumb implant design philosophy will be expanded to other joint implant prostheses and therapies.
With the development and commercialization of its ZEPART thumb implant, Sandia Medical Technologies is working to establish itself as an emerging R&D leader for the orthopedic surgery industry, most especially in the upper extremities. The company plans to replicate the ZEPART R&D development model in addressing additional surgical treatment needs for this orthopedic demographic.
For ZEPART, we anticipate being able to follow an already established regulatory pathway based on similar technologies already having received regulatory clearances.
